Chiasma and FDA agree on new Phase III trial design for acromegaly drug

The US Food and Drug Administration (FDA) has agreed on biopharmaceutical firm Chiasma ’s new Phase III clinical trial (OPTIMAL) design to evaluate its octreotide capsules product candidate Mycapssa as a maintenance therapy to treat adults with acrome…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

What multimodal therapeutic options are needed to achieve successful remission in persistent acromegaly?Endocrine Practice
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Conditions:   Cushing Syndrome;   Acromegaly Intervention:   Other: MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing Sponsor:   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Recruiting
Source: - Category: Research Source Type: clinical trials
Clinical Endocrinology,Volume 0, Issue ja, -Not available-.
Source: Clinical Endocrinology - Category: Endocrinology Authors: Source Type: research
AbstractObjectiveMultiple studies investigated preclinical markers of peripheral vascular damage in acromegaly (ACRO) reporting discordant results. The aim of this study was to run a meta-analysis to examine whether intima media thickness (IMT), flow mediated dilation (FMD) and arterial pulse wave velocity (PWV) are affected in acromegalic patients and to assess the impact of effective treatment of growth hormone excess on these outcomes.Study selectionTwenty-seven studies comparing ACRO vs control (CON) populations and active (ACT) vs inactive (INACT) ACRO were included in the meta-analysis.Data synthesisACRO compared to ...
Source: Pituitary - Category: Endocrinology Source Type: research
CONCLUSIONS Acromegalics with tumors that stain for prolactin and GH, which represented almost a quarter of acromegalics in this cohort, had more aggressive clinical presentations and postoperative outcomes than SSAs. Prolactin staining provides useful information for acromegalics undergoing pituitary surgery. PMID: 30215558 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - Category: Neurosurgery Authors: Tags: J Neurosurg Source Type: research
We report clinicopathological features of a large series of synchronous multiple pituitary neuroendocrine tumors (PitNETs) of different cell lineages. Retrospective review of pathology records from 2001 to 2016 identified 13 synchronous multiple PitNETs from 1055 PitNETs classified using pituitary cell-lineage transcription factors, adenohypohyseal hormones, and other biomarkers. Clinical, radiological, and histopathological features of these tumors were reviewed. The series included seven females and six males. Mean age at diagnosis was 55.23  years (range 36–73). Imaging was unavailable for four patients; amon...
Source: Endocrine Pathology - Category: Pathology Source Type: research
ConclusionThe perioperative dynamic distribution of the facial and abdominal fat in acromegaly revealed regional differences in the intricate effect of GH on adipose tissue. Reduction of serum GH after surgical treatment of acromegaly was associated with dynamic increases of IHL, abdominal visceral, and subcutaneous fat, but a reduction of facial subcutaneous fat.
Source: Endocrine - Category: Endocrinology Source Type: research
Authors: Gadelha MR, Kasuki L, Lim DS, Fleseriu M Abstract Acromegaly is a chronic systemic disease with many complications and is associated with increased mortality when not adequately treated. Significant advances in acromegaly treatment, as well as in the treatment of many of its complications, mainly diabetes mellitus, heart failure and arterial hypertension, were achieved in the last decades. These developments allowed change in both prevalence and severity of some acromegaly complications and furthermore resulted in a reduction of mortality. Nowadays, mortality seems to be similar to the general population i...
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research
We report our experience about somatotrophinomas without clinical manifestation of acromegaly having radiological- and surgical-verified invasion of the cavernous sinus. We present the clinical, radiological and hormonal status of three patients affected by invasive GH-secreting pituitary adenomas without clinical signs and symptoms of acromegaly with elevation of serum IGF-1 from a series of 142 pituitary adenomas operated in our institute with the aid of intraoperative magnetic resonance imaging (MRI). Total tumor removal was possible in two of the three cases; the patients show normal hormonal status and no recurrence a...
Source: Neurosurgical Review - Category: Neurosurgery Source Type: research
Publication date: Available online 1 September 2018Source: HOMOAuthor(s): Michael Shterenshis, Yulia Roitblat, Sari Rosenberg, Monica Singer, Jeanne LumbrosoAbstractThis paper examines the role of the history of medicine in case of congenital isolated hemihyperplasia. Isolated hemihyperplasia is a genetic disorder in which one side of the body grows more than the other, causing visible lateral asymmetry of the human body. The date of the occurrence of the genetic mutation that leads to hemihyperplasia is not known yet. The aim of the current research was to confirm or to disprove the fact that isolated hemihyperplasia was ...
Source: HOMO Journal of Comparative Human Biology - Category: Biology Source Type: research
More News: Acromegaly | Clinical Trials | Food and Drug Administration (FDA) | Pharmaceuticals